Document Detail

Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.
MedLine Citation:
PMID:  20035894     Owner:  NLM     Status:  MEDLINE    
Despite important improvements over the past two decades, the overall cure rate of epithelial ovarian cancer (EOC) remains only approximately 30%. Although much has been learned about the proteins and pathways involved in early events of malignant transformation and drug resistance, a major challenge still remaining is the identification of markers for early diagnosis and prediction of response to chemotherapy. Recently, it has become clear that alterations in the expression of microRNAs (miRNAs) contribute to the pathogenesis and progression of several human malignancies. In this review we discuss current data concerning the accumulating evidence of the role of miRNAs in EOC pathogenesis and tumor characterization; their dysregulated expression in EOC; and their still undefined role in diagnosis, prognosis and prediction of response to therapy. The most frequently deregulated miRNAs are members of the let-7 and miR-200 families, the latter involved in epithelial-to-mesenchymal transition (EMT). EMT is part of normal ovarian surface epithelium physiology, being the key regulator of the post-ovulatory repair process, and failure to undergo EMT may be one of the events leading to transformation. A general down-modulation of miRNA expression is observed in EOC compared to normal tissue. However, a clear consensus on the miRNA signatures associated with prognosis or prediction of response to therapy has not yet been reached.
Delia Mezzanzanica; Marina Bagnoli; Loris De Cecco; Barbara Valeri; Silvana Canevari
Related Documents :
15864374 - Relationship between thymidylate synthase (ts) genotype and ts expression: a tissue mic...
19495974 - Prognostic significance of herg1 expression in gastric cancer.
10769634 - Relevant genomics of neurotensin receptor in cancer.
16033834 - Ephb2 is a prognostic factor in colorectal cancer.
17684404 - Diet and genomic stability.
10048254 - Choosing an opioid analgesic for cancer patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2009-12-24
Journal Detail:
Title:  The international journal of biochemistry & cell biology     Volume:  42     ISSN:  1878-5875     ISO Abbreviation:  Int. J. Biochem. Cell Biol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-12     Completed Date:  2010-10-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508482     Medline TA:  Int J Biochem Cell Biol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1262-72     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Elsevier Ltd. All rights reserved.
Unit of Molecular Therapies, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Gene Expression Regulation, Neoplastic
MicroRNAs / biosynthesis,  genetics,  metabolism*
Ovarian Neoplasms / diagnosis,  etiology*,  genetics*,  pathology
Tumor Markers, Biological / genetics,  metabolism
Reg. No./Substance:
0/MicroRNAs; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  De novo formation of Basal bodies During Cellular Differentiation of Naegleria gruberi: Progress and...
Next Document:  NFATc1: Functions in osteoclasts.